UBS raises Clover Health’s price target by 73% citing 51.31% projected EPS growth over five years and improving profitability.
UBS analyst Jonathan Yong increased Clover Health Investments Corp.’s (NASDAQ:CLOV) price target to $4.75 from $2.75, maintaining a Neutral rating. The revision reflects growing confidence in the company’s operational outlook and execution on profitability initiatives.
The firm highlighted CLOV’s 51.31% projected EPS growth over the next five years, positioning it among top long-term quality stocks. Earlier, Canaccord raised its target to $4.20 from $3.20, citing strong performance in April and May and broader industry tailwinds.
Clover Health, a technology-driven healthcare provider, continues to expand its platform capabilities amid improving managed care conditions.